Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Page standards status: Informative |
<Library xmlns="http://hl7.org/fhir">
<id value="179618"/>
<meta>
<versionId value="3"/>
<lastUpdated value="2023-11-26T21:01:14.757Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-included-studies"/>
</meta>
<language value="en"/>
<text>
<status value="extensions"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<table class="narrative-table">
<tbody>
<tr>
<th colspan="2" scope="row" class="row-header">Metadata</th>
</tr>
<tr>
<th scope="row" class="row-header">Title</th>
<td class="content-container">SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer</td>
</tr>
<tr>
<th scope="row" class="row-header">Version</th>
<td class="content-container">1.0.0-ballot3</td>
</tr>
<tr>
<th scope="row" class="row-header">Identifier</th>
<td class="content-container">179618</td>
</tr>
<tr>
<th scope="row" class="row-header">Identifier</th>
<td class="content-container">urn:oid:2.16.840.1.113883.4.642.40.44.28.3</td>
</tr>
<tr>
<th scope="row" class="row-header">Subject Type</th>
<td class="content-container"><a href="Group-179619.html">SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer</a></td>
</tr>
<tr>
<th scope="row" class="row-header">Use Context</th>
<td class="content-container">
Evidence Communication
=
SystematicReviewIncludedStudies
</td>
</tr>
<tr>
<th scope="row" class="row-header">Jurisdiction</th>
<td class="content-container">
World
</td>
</tr>
<tr>
<th scope="row" class="row-header">Steward (Publisher)</th>
<td class="content-container">HL7 International / Clinical Decision Support</td>
</tr>
<tr>
<th scope="row" class="row-header">Steward Contact</th>
<td class="content-container">HL7 International / Clinical Decision Support</td>
</tr>
<tr>
<th scope="row" class="row-header">Developer</th>
<td class="content-container">Brian S. Alper</td>
</tr>
<tr>
<th scope="row" class="row-header">Description</th>
<td class="content-container"><div><p>3 included studies</p>
</div></td>
</tr>
<tr>
<th scope="row" class="row-header">Copyright</th>
<td class="content-container"><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div></td>
</tr>
<tr>
<th scope="row" class="row-header">Type</th>
<td class="content-container">
Asset Collection
</td>
</tr>
<tr>
<td class="content-container">
</td>
</tr>
<tr>
<td class="content-container">
</td>
</tr>
<tr>
<td class="content-container">
</td>
</tr>
<tr>
<td class="content-container">
</td>
</tr>
<tr>
<th colspan="2" scope="row" class="row-header"><a name="parameters"> </a>Parameters</th>
</tr>
<tr>
<th scope="row" class="row-header">Parameter</th>
<td class="content-container">None</td>
</tr>
<tr>
<th colspan="2" scope="row" class="row-header">Generated using version 0.5.4 of the sample-content-ig Liquid templates</th>
</tr>
</tbody>
</table>
</div>
</text>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status">
<valueCodeableConcept>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/cited-artifact-status-type"/>
<code value="active"/>
<display value="Active"/>
</coding>
</valueCodeableConcept>
</extension>
<url value="https://fevir.net/resources/Library/179618"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net/FOI"/>
<value value="179618"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<identifier>
<system value="urn:ietf:rfc:3986"/>
<value value="urn:oid:2.16.840.1.113883.4.642.40.44.28.3"/>
</identifier>
<version value="1.0.0-ballot3"/>
<title
value="SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"/>
<status value="active"/>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/library-type"/>
<code value="asset-collection"/>
<display value="Asset Collection"/>
</coding>
</type>
<subjectReference>🔗
<reference value="Group/179619"/>
<type value="Group"/>
<display
value="SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"/>
</subjectReference>
<date value="2023-11-26T18:15:27.442Z"/>
<publisher value="HL7 International / Clinical Decision Support"/>
<contact>
<name value="HL7 International / Clinical Decision Support"/>
<telecom>
<system value="url"/>
<value value="http://www.hl7.org/Special/committees/dss"/>
</telecom>
</contact>
<description value="3 included studies"/>
<useContext>
<code>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="evidence-communication"/>
<display value="Evidence Communication"/>
</code>
<valueCodeableConcept>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="SystematicReviewIncludedStudies"/>
<display value="SystematicReviewIncludedStudies"/>
</coding>
</valueCodeableConcept>
</useContext>
<jurisdiction>
<coding>
<system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/>
<code value="001"/>
<display value="World"/>
</coding>
</jurisdiction>
<copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
<author>
<name value="Brian S. Alper"/>
</author>
<relatedArtifact>
<type value="derived-from"/>
<resourceReference>🔗
<reference value="Citation/179613"/>
<type value="Citation"/>
<display
value="27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis."/>
</resourceReference>
</relatedArtifact>
<relatedArtifact>
<type value="contains"/>
<resourceReference>🔗
<reference value="Citation/179615"/>
<type value="Citation"/>
<display
value="23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial."/>
</resourceReference>
</relatedArtifact>
<relatedArtifact>
<type value="contains"/>
<resourceReference>🔗
<reference value="Citation/179617"/>
<type value="Citation"/>
<display
value="25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the 'Docetaxel Era': Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)."/>
</resourceReference>
</relatedArtifact>
<relatedArtifact>
<type value="contains"/>
<resourceReference>🔗
<reference value="Citation/179616"/>
<type value="Citation"/>
<display
value="26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer."/>
</resourceReference>
</relatedArtifact>
</Library>